Most of the clinical trials that are currently active or recruiting patients do not take into account EGFR status, neither by mutation analysis, gene amplification nor IHC expression. Pathologists ...
Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by in situ hybridization. Mechanisms of EGFR upregulation are dependent on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback